Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : to shut two manufacturing plants in India

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2019 | 01:08pm EDT
FILE PHOTO: Logo of U.S. pharmaceutical corporation Pfizer Inc. is seen in Zurich

(Reuters) - U.S. drugmaker Pfizer Inc said on Wednesday it was shutting down two manufacturing plants in India that make generic injectables like penicillin as a response to falling demand.

Indian financial newspaper Business Standard reported https://www.business-standard.com/article/companies/pfizer-to-stop-manufacturing-operations-in-chennai-aurangabad-units-119010801430_1.html the news on Tuesday, saying over 1,700 employees would be impacted by the closure of the two factories in the states of Tamil Nadu and Maharashtra.

The factories employ nearly 6 percent of Pfizer's global manufacturing workforce.

"Pfizer has conducted a thorough evaluation of the ... sites in India and concluded that due to the very significant long term loss of product demand, manufacturing at these sites is not viable," the company said in an emailed statement.

Pfizer acquired the sites as part of its $15 billion (£11.7 billion) purchase of Hospira Inc in 2015, to boost its portfolio of generic injectable drugs and copies of biotech medicines.

The plant in Chennai makes generic injectable cephalosporin, penems and penicillin. The Maharashtra plant supplied the Chennai unit with certain products.

Both plants do not manufacture products for the India market, Pfizer said, adding that it is expanding operations in its Visakhapatnam facility in south India.

(The story corrects the third paragraph to show plants employ nearly 6 percent of manufacturing workforce, not total workforce)

(Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
03/23PFIZER : buys stake in French gene therapy company Vivet
AQ
03/21PFIZER : Description Notice of exempt solicitation. Definitive material.
PU
03/21ERNESTO BERTARELLI : French healthcare group Stallergenes to be bought out by Be..
RE
03/21PFIZER : Adds to Streak of Deals in Gene Therapies
DJ
03/20Merck KGaA, Pfizer End Phase III Trial in Previously Untreated Advanced Ovari..
DJ
03/20PFIZER : Adds to Big Pharma's Gene-Therapy Deal Streak
DJ
03/20PFIZER : Takes 15% Stake in Gene-Therapy Biotech Vivet Therapeutics
DJ
03/20PFIZER : Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeu..
BU
03/19MERCK KGAA : Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase II..
PR
03/19PFIZER : Invites Public to View and Listen to Webcast of April 30 Conference Cal..
BU
More news
Financials ($)
Sales 2019 53 331 M
EBIT 2019 19 994 M
Net income 2019 12 143 M
Debt 2019 32 038 M
Yield 2019 3,43%
P/E ratio 2019 19,27
P/E ratio 2020 16,75
EV / Sales 2019 4,96x
EV / Sales 2020 4,85x
Capitalization 232 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 44,1 $
Spread / Average Target 5,5%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-4.12%232 343
JOHNSON & JOHNSON6.09%364 560
NOVARTIS10.71%239 248
ROCHE HOLDING LTD.10.68%233 745
MERCK AND COMPANY7.70%212 409
ELI LILLY AND COMPANY10.87%132 844